Nuvectis Pharma (NVCT) Competitors $6.52 +0.17 (+2.68%) Closing price 04:00 PM EasternExtended Trading$6.58 +0.06 (+0.84%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. IMTX, ABUS, GHRS, KALV, KURA, BCAX, RLAY, KROS, SNDL, and MGTXShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Immatics (IMTX), Arbutus Biopharma (ABUS), GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), SNDL (SNDL), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Immatics Arbutus Biopharma GH Research KalVista Pharmaceuticals Kura Oncology Bicara Therapeutics Relay Therapeutics Keros Therapeutics SNDL MeiraGTx Nuvectis Pharma (NASDAQ:NVCT) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Which has preferable earnings and valuation, NVCT or IMTX? Immatics has higher revenue and earnings than Nuvectis Pharma. Immatics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$19M-$1.17-5.57Immatics$130.13M5.34$16.47M-$0.65-8.80 Do institutionals and insiders believe in NVCT or IMTX? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, NVCT or IMTX? Nuvectis Pharma has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do analysts prefer NVCT or IMTX? Nuvectis Pharma presently has a consensus price target of $15.33, indicating a potential upside of 135.17%. Immatics has a consensus price target of $14.67, indicating a potential upside of 156.41%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Immatics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is NVCT or IMTX more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Immatics' net margin of -59.29%. Immatics' return on equity of -15.60% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -150.81% -94.84% Immatics -59.29%-15.60%-12.31% Does the media prefer NVCT or IMTX? In the previous week, Immatics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Immatics and 2 mentions for Nuvectis Pharma. Immatics' average media sentiment score of 1.14 beat Nuvectis Pharma's score of 0.00 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryImmatics beats Nuvectis Pharma on 11 of the 16 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.00M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-5.5721.0283.0126.65Price / SalesN/A379.56503.03163.66Price / CashN/A43.5325.7028.92Price / Book9.888.1210.796.52Net Income-$19M-$53.35M$3.29B$266.21M7 Day Performance-0.15%0.05%0.02%-0.76%1 Month Performance-10.56%7.08%7.06%3.83%1 Year Performance-1.36%11.92%50.09%24.39% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.7944 of 5 stars$6.52+2.7%$15.33+135.2%-6.6%$166.00MN/A-5.578News CoverageIMTXImmatics2.3924 of 5 stars$5.23-8.1%$14.67+180.4%-50.7%$691.62M$130.13M-8.05260Positive NewsABUSArbutus Biopharma2.5964 of 5 stars$3.50-2.5%$5.50+57.1%-1.5%$688.20M$6.17M-12.0790News CoveragePositive NewsGHRSGH Research1.7254 of 5 stars$13.18+0.8%$32.00+142.8%+42.9%$680.53MN/A-17.8110News CoverageKALVKalVista Pharmaceuticals4.0623 of 5 stars$12.99-3.1%$26.29+102.4%+14.5%$675.06MN/A-3.52100News CoveragePositive NewsKURAKura Oncology3.8232 of 5 stars$7.65flat$24.10+215.0%-58.3%$664M$53.88M-3.38130News CoveragePositive NewsAnalyst ForecastBCAXBicara Therapeutics2.3793 of 5 stars$11.32-4.4%$32.25+184.9%N/A$646.03MN/A-3.5732RLAYRelay Therapeutics2.0177 of 5 stars$3.51-4.9%$17.08+386.7%-36.5%$636.20M$8.36M-1.80330News CoverageAnalyst ForecastKROSKeros Therapeutics3.6198 of 5 stars$14.76-5.1%$30.00+103.3%-67.0%$631.97M$232.84M47.61100News CoveragePositive NewsSNDLSNDL3.487 of 5 stars$2.40+6.7%$4.00+66.7%+27.9%$630.66M$944.25M-8.892,516News CoverageAnalyst ForecastMGTXMeiraGTx4.5065 of 5 stars$7.58-3.2%$24.00+216.6%+87.5%$629.90M$33.28M-3.72300News CoveragePositive News Related Companies and Tools Related Companies IMTX Alternatives ABUS Alternatives GHRS Alternatives KALV Alternatives KURA Alternatives BCAX Alternatives RLAY Alternatives KROS Alternatives SNDL Alternatives MGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVCT Stock Alerts